Press Release
January 4, 2024

HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases

The Life Sciences team advised Human Immunology Biosciences (HI-Bio) in its $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.

Funding from the Series B will be used to advance clinical development of felzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies.

HI-Bio is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases.

The Goodwin team was led by Maggie Wong, Kingsley Taft, Sara Wolf, Sofie Dohil, Gozde Guckaya, Jake Osborn, Kevin Kabler, Katerina Stavrianidis, Paresh Kumar, Tricia Hojo, and Ruowen Li.

For more details, read the press release and coverage in Endpoints News and Fierce Biotech.